Search results
Results From The WOW.Com Content Network
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia , and Vaxxinity, Inc. [2] It is a peptide vaccine. [3] [4] It is composed of SARS-CoV-2 S1-RBD protein and synthetic peptides representing T cell (Th and CTL) epitopes on the nucleocapsid, spike and membrane proteins. The multitope composition is differentiated from ...
N1-Methylpseudouridine is the methylated derivative of pseudouridine.It is used in in vitro transcription and for the production of RNA vaccines. [3] [4] In vertebrates, it stimulates significantly less activation of the innate immune response compared to uridine, [5] while the translation is stronger.
According to the Korean Ministry of Food and Drug Safety, vaccine-related adverse events occurred in 13.3% of the vaccine group. In the control group, the adverse event rate was about 14.6%, which was not different from the vaccine group. Serious adverse events occurred in 0.5% in the vaccine group and 0.5% in the control group.
The preparation of ALC-0315 was first described in a patent application to lipid nanoparticles by Acuitas Therapeutics in 2017. [6]: 137 The final step is a reductive amination reaction in which 4-aminobutanol is condensed with a lipid aldehyde, using sodium triacetoxyborohydride as the reducing agent to convert the intermediate imines to the amine of the product.
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [2] [3] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [ 4 ]
The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, [1] is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, [24] and its Belgian parent company Janssen Pharmaceuticals, [25] a subsidiary of American company Johnson & Johnson.
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [2] [3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...
SM-102 is a synthetic amino lipid which is used in combination with other lipids to form lipid nanoparticles. [1] These are used for the delivery of mRNA-based vaccines, [2] [3] [4] and in particular SM-102 forms part of the drug delivery system for the Moderna COVID-19 vaccine.